PCSK9 and coronary artery disorder: ASGR1 mutations may have a strong impact on CHD risk, but not as large as for PCSK9 or APOC3.7,16,25,26 PCSK9 partial LOF mutations (e.g. R46L) have been associated with 30% reduction in CHD risk in three independent studies and meta-analyses (odds ratio 0.70, 95% CI: 0.58–0.86, p < 0.001).25 Moreover, complete LOF mutations of PCSK9 (as is the case of ASGR1 del12 or W158X mutations) result in 88% reduction in CV events over 15 years.26 On the other hand carriers of APOC3 LOF mutation had 40% lower risk of CHD than that in non-carriers (odds ratio 0.60; 95% CI: 0.47 to 0.75; p = 4 × 10−6).7